The effect of HMG and recombinant human FSH on oocyte quality: a randomized single-blind clinical trial

Eur J Obstet Gynecol Reprod Biol. 2005 Jun 1;120(2):190-4. doi: 10.1016/j.ejogrb.2004.11.007.

Abstract

Objective: To compare the effect of HMG and rhFSH on oocyte quality in ICSI cycle.

Setting: Vali-e-Asr university teaching hospital.

Method: Prospective single-blind randomized clinical trial.

Subjects: Sixty women undergoing ovarian stimulation for ICSI were randomized to receive a standard protocol of either HMG or rhFSH in down-regulation cycles.

Interventions: Prior to microinjection, each oocyte was assessed regarding the nuclear maturity, morphology of zona plucida, cytoplasmic appearance and polar body morphology. Fertilization rate was followed.

Main outcome: The percentage of metaphase II oocytes in HMG and rhFSH groups.

Statistical analysis: Statistical analyses were carried out by the Mann-Whitney, Fisher's exact, chi2 tests and Student's t-test.

Results: No significant differences were found between two groups in regard to the demographic data, the ovarian response and pregnancy/implantation rates (P>0.05). The percentage of metaphase II oocytes in HMG and rhFSH groups were 81.3% versus 80.6%, respectively.

Conclusions: There were no significant differences between parameters such as, oocyte quality and percentage of metaphase II oocytes between these two groups.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Embryo Implantation
  • Embryo Transfer
  • Female
  • Follicle Stimulating Hormone / administration & dosage*
  • Humans
  • Menotropins / administration & dosage*
  • Microinjections
  • Oocytes / drug effects*
  • Ovulation Induction
  • Pregnancy
  • Prospective Studies
  • Recombinant Proteins

Substances

  • Recombinant Proteins
  • Menotropins
  • Follicle Stimulating Hormone